LXRX - Lexicon Pharmaceuticals, Inc.
| Previous Close | 10.71 |
| Open | 10.76 |
| Bid | 10.20 x 1800 |
| Ask | 12.48 x 800 |
| Day's Range | 10.46 - 10.79 |
| 52 Week Range | 7.67 - 13.97 |
| Volume | 846,288 |
| Avg. Volume | 412,562 |
| Market Cap | 1.11B |
| Beta | 1.87 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.29 |
| Earnings Date | Nov 6, 2018 - Nov 12, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 28.75 |
Markit•3 days agoSee what the IHS Markit Score report has to say about Lexicon Pharmaceuticals Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- Benzinga•7 days ago
The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs
Biotech were trending mostly sideways in the week ending Sept. 14 after posting weekly gains in the previous two weeks. Notwithstanding the overall muted sentiment, there was some activity in reaction ...
Markit•8 days agoSee what the IHS Markit Score report has to say about Lexicon Pharmaceuticals Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- GlobeNewswire•24 days ago
Lexicon Pharmaceuticals to Present at Upcoming Investor Conference
A live audio webcast for this conference will be available in the “Investors” section of the Lexicon website at www.lexpharma.com/. Lexicon is a fully integrated biopharmaceutical company that is applying a unique approach to gene science based on Nobel Prize-winning technology to discover and develop precise medicines for patients with serious, chronic conditions.
- GlobeNewswire•26 days ago
Research Report Identifies Convergys, Amkor Technology, Discovery, Inc., ServiceMaster Global, Acadia Healthcare, and Lexicon Pharmaceuticals with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Aug. 28, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Convergys ...
Markit•26 days agoSee what the IHS Markit Score report has to say about Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc NASDAQ/NGS:LXRX
- GlobeNewswire•last month
UPDATE: Lexicon Pharmaceuticals to Present at Upcoming Investor Conference
A live audio webcast for this conference will be available in the “Investors” section of the Lexicon website at www.lexpharma.com/. Lexicon is a fully integrated biopharmaceutical company that is applying a unique approach to gene science based on Nobel Prize-winning technology to discover and develop precise medicines for patients with serious, chronic conditions. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease.
- GlobeNewswire•last month
Lexicon Pharmaceuticals to Present at Upcoming Investor Conference
A live audio webcast for this conference will be available in the “Investors” section of the Lexicon website at www.lexpharma.com/. Lexicon is a fully integrated biopharmaceutical company that is applying a unique approach to gene science based on Nobel Prize-winning technology to discover and develop precise medicines for patients with serious, chronic conditions. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of LXRX earnings conference call or presentation 30-Jul-18 12:00pm GMT
Q2 2018 Lexicon Pharmaceuticals Inc Earnings Call
- GlobeNewswire•2 months ago
Lexicon Pharmaceuticals to Present at Upcoming Investor Conference
A live audio webcast for this conference will be available in the “Investors” section of the Lexicon website at www.lexpharma.com/. Lexicon is a fully integrated biopharmaceutical company that is applying a unique approach to gene science based on Nobel Prize-winning technology to discover and develop precise medicines for patients with serious, chronic conditions. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease.
- Zacks•2 months ago
Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Misses Revenue Estimates
Lexicon (LXRX) delivered earnings and revenue surprises of 5.71% and -17.37%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire•2 months ago
Lexicon Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides a Business Update
Net Sales of $6.0 Million, Up 65% from Prior Year Quarter and 11% Quarter-Over-Quarter. Filings for Regulatory Approval of Sotagliflozin in Type 1 Diabetes Accepted. THE WOODLANDS, Texas, July 30, 2018-- ...
- ACCESSWIRE•2 months ago
Lexicon Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / July 30, 2018 / Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) will be discussing their earnings results in their Q2 Earnings Call to be held on July 30, 2018 at 8:00 AM Eastern ...
- Benzinga•2 months ago
The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs
Biotech stocks saw modest gains this week, with earnings providing a boost even as clinical trial results elicited a mixed reaction. Eli Lilly And Co (NYSE: LLY ), Vertex Pharmaceuticals Incorporated (NASDAQ: ...
- PR Newswire•2 months ago
New Insights Revealed in National Survey Show More Advances Are Needed for the Type 1 Diabetes Community
JACKSONVILLE, Fla., July 26, 2018 /PRNewswire/ -- The American Association of Clinical Endocrinologists (AACE) today announced results of two recent online surveys, conducted by The Harris Poll that assessed the attitudes of endocrinologists and adults living with type 1 diabetes (T1D) in the United States. More than 70 percent of endocrinologists and adults with T1D surveyed stated that recent advances in T1D give them hope that there will eventually be a cure, yet an overwhelming majority agreed that more advances are currently needed to help improve the lives of those with the disease.
- GlobeNewswire•2 months ago
UPDATE - Lexicon Pharmaceuticals to Host Second Quarter 2018 Financial Results Conference Call and Webcast on July 30, 2018
Lexicon Pharmaceuticals, Inc. (LXRX), will release its second quarter 2018 financial results on Monday, July 30, 2018 before market opens. Management will conduct a conference call and live webcast at 8:00 a.m. EDT (7:00 a.m. CDT) that day to discuss the financial results and to provide a business update.
- GlobeNewswire•2 months ago
Lexicon Pharmaceuticals to Host First Quarter 2018 Financial Results Conference Call and Webcast on July 30, 2018
Lexicon Pharmaceuticals, Inc. (LXRX), will release its second quarter 2018 financial results on Monday, July 30, 2018 before market opens. Management will conduct a conference call and live webcast at 8:00 a.m. EDT (7:00 a.m. CDT) that day to discuss the financial results and to provide a business update.
Markit•2 months agoSee what the IHS Markit Score report has to say about Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc NASDAQ/NGS:LXRX
- ACCESSWIRE•2 months ago
Free Technical Research on Marinus Pharma and Three More Biotech Equities
LONDON, UK / ACCESSWIRE / July 16, 2018 / If you want a free Stock Review on MRNS sign up now at www.wallstequities.com/registration. On Friday, July 13, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Six out of nine sectors ended Friday's trading session in bullish territories.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of LXRX earnings conference call or presentation 3-May-18 12:00pm GMT
Q1 2018 Lexicon Pharmaceuticals Inc Earnings Call
- Benzinga•3 months ago
Insider Buys Of The Week: AbbVie, Energen, NuStar And More
An activist investor took the next step in acquiring his target. Conventional wisdom says that insiders and 10-percent owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit. Energen Corporation (NYSE: EGN) saw renowned activist investor Carl Icahn increase his stake this past week.
- Simply Wall St.•3 months ago
Should You Follow This Trend For Lexicon Pharmaceuticals Inc (NASDAQ:LXRX)?
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. Lexicon Pharmaceuticals’s insiders have invested 295.42k shares in theRead More...
- GlobeNewswire•3 months ago
Research Report Identifies Citizens Financial Group, Fifth Third, KKR & Co., Vista Outdoor, Devon Energy, and Lexicon Pharmaceuticals with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, June 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Citizens ...
- Benzinga•3 months ago
Insider Buys Of The Week: DDR, Salesforce, Lexicon Pharma
Conventional wisdom says that insiders and 10 percent owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. While the CEO, president and other salesforce.com, inc. (NYSE: CRM) executives and insiders were selling throughout June, one director stepped up to the buy window this past week.
